No association of polymorphisms in the gene encoding 5-lipoxygenase-activating protein and myocardial infarction in a large central European population

Purpose: Haplotypes based on polymorphisms in the gene encoding 5-lipoxygenase-activating protein have been linked with susceptibility to myocardial infarction in Iceland and the United Kingdom. We sought to replicate these association findings in a large case-control sample from Germany. Methods: The case group included 3657 patients with myocardial infarction and the control group comprised 1211 individuals with angiographically normal coronary arteries and without clinical signs or symptoms of myocardial infarction. Nine different polymorphisms were genotyped with the use of the TaqMan technique. Results: Genotype, allele, and haplotype analyses did not reveal significant associations between the polymorphisms and myocardial infarction. The negative results included a four-marker haplotype, termed HapA haplotype (odds ratio = 1.10; 95% confidence interval: 0.96-1.25), that was previously found to be related with myocardial infarction in a sample from Iceland, and a different four-marker haplotype, termed HapB haplotype (odds ratio = 0.94; 95% CI: 0.79-1.12), that was previously linked with myocardial infarction in a sample from the United Kingdom. Nine-marker haplotypes were not significantly associated with myocardial infarction in multiple logistic regression models adjusted for covariates (P >= 0.38). Conclusion: In this sample from central Europe, specific polymorphisms in the gene for 5-lipoxygenase-activating protein were not associated with myocardial infarction, a result contrasting previous positive findings.